L&C Bio Co., Ltd (290650.KQ)

KRW 22600.0

(1.8%)

EBITDA Summary of L&C Bio Co., Ltd

L&C Bio Co., Ltd's latest annual EBITDA in 2023 was 13.4 Billion KRW , up 1.79% from previous year.
L&C Bio Co., Ltd's latest quarterly EBITDA in 2024 Q2 was 2.6 Billion KRW , down -7.16% from previous quarter.
L&C Bio Co., Ltd reported an annual EBITDA of 14.24 Billion KRW in 2022, down -32.59% from previous year.
L&C Bio Co., Ltd reported an annual EBITDA of 16.07 Billion KRW in 2021, up 35.35% from previous year.
L&C Bio Co., Ltd reported a quarterly EBITDA of 2.6 Billion KRW for 2024 Q2, down -7.16% from previous quarter.
L&C Bio Co., Ltd reported a quarterly EBITDA of 3.45 Billion KRW for 2023 Q1, down -4.76% from previous quarter.

Annual EBITDA Chart of L&C Bio Co., Ltd (2023 - 2015)

Historical Annual EBITDA of L&C Bio Co., Ltd (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	13.4 Billion KRW	1.79%
2022	14.24 Billion KRW	-32.59%
2021	16.07 Billion KRW	35.35%
2020	8.91 Billion KRW	36.66%
2019	10.11 Billion KRW	78.59%
2018	6.39 Billion KRW	18.64%
2017	5.16 Billion KRW	93.53%
2016	2.82 Billion KRW	78.24%
2015	1.65 Billion KRW	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	3.11 Billion KRW	-18.3%
2024 Q2	2.6 Billion KRW	-7.16%
2023 Q1	3.45 Billion KRW	-4.76%
2023 Q4	2.19 Billion KRW	-53.85%
2023 FY	- KRW	1.79%
2023 Q2	1.61 Billion KRW	-53.28%
2023 Q3	4.75 Billion KRW	194.65%
2022 Q2	4 Billion KRW	32.99%
2022 FY	- KRW	-32.59%
2022 Q4	3.62 Billion KRW	35.08%
2022 Q3	2.68 Billion KRW	-32.9%
2022 Q1	3 Billion KRW	-69.43%
2021 Q2	4.3 Billion KRW	74.76%
2021 Q3	4.05 Billion KRW	-5.71%
2021 Q4	9.84 Billion KRW	142.38%
2021 FY	- KRW	35.35%
2021 Q1	2.46 Billion KRW	-69.39%
2020 Q3	2.83 Billion KRW	20.35%
2020 Q4	8.04 Billion KRW	184.17%
2020 FY	- KRW	36.66%
2020 Q1	2 Billion KRW	-50.31%
2020 Q2	2.35 Billion KRW	17.62%
2019 Q4	4.02 Billion KRW	74.34%
2019 FY	- KRW	78.59%
2019 Q3	2.3 Billion KRW	-14.72%
2019 Q2	2.7 Billion KRW	33.95%
2019 Q1	2.02 Billion KRW	9.9%
2018 Q2	1.56 Billion KRW	0.41%
2018 Q1	1.56 Billion KRW	0.0%
2018 Q3	1.26 Billion KRW	-19.32%
2018 Q4	1.83 Billion KRW	45.35%
2018 FY	- KRW	18.64%
2017 FY	- KRW	93.53%
2016 FY	- KRW	78.24%
2015 FY	- KRW	0.0%

Peer EBITDA Comparison of L&C Bio Co., Ltd

Name	EBITDA	EBITDA Difference
Osang Healthcare Co.,Ltd	157.89 Billion KRW	91.512%
InBody Co.,Ltd	44.25 Billion KRW	69.718%
Curexo Inc.	-2.75 Billion KRW	586.709%
Seegene, Inc.	35.65 Billion KRW	62.412%
i-SENS, Inc.	24.14 Billion KRW	44.492%
Ray Co., Ltd.	7.62 Billion KRW	-75.786%
Gencurix Inc.	-18.09 Billion KRW	174.075%
Sugentech Inc.	-12.13 Billion KRW	210.475%